Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(Encorafenib; LGX 818; LGX-818)
LGX818 Chemical Structure
|Product name: LGX818|
|Cat. No.: HY-15605|
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
IC50 value: 0.3 nM (BRaf V600E biochemical); 2 nM (A375 cell proliferation) 
Target: mutated BRaf V600E
LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis, is in phase III clinical trials, and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans. More information can be found in Patent WO2011025927A1
|M.Wt||540.01||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
in DMSO > 10 mM
|1 mg||5 mg||10 mg|
|1 mM||1.8518 mL||9.2591 mL||18.5182 mL|
|5 mM||0.3704 mL||1.8518 mL||3.7036 mL|
|10 mM||0.1852 mL||0.9259 mL||1.8518 mL|
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.
B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).
A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.
BRAF inhibitor is a potent BRAF inhibitor.
GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.
GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.
HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38(alpha), GSK3(beta) and Lck respectively.
LY3009120 is a small molecule that has been shown in vitro to be a pan-RAF inhibitor of all isoforms, blocking proliferation in both BRAF and RAS mutant cells.
MLN 2480(BIIB-024) is an oral, selective pan-Raf kinase inhibitor in chinical trials.